Research on the Drug Auxiliary Catalog for Tumor Diseases and the Payment Policy of Daytime Chemotherapy Under the DIP Payment

China Health Insurance ›› 2024, Vol. 0 ›› Issue (9) : 64-69.

China Health Insurance ›› 2024, Vol. 0 ›› Issue (9) : 64-69. DOI: 10.19546/j.issn.1674-3830.2024.9.009
Observation & Discussion

Research on the Drug Auxiliary Catalog for Tumor Diseases and the Payment Policy of Daytime Chemotherapy Under the DIP Payment

Author information +
History +

Abstract

Objective: The paper attempts to explore the drug auxiliary catalog setting and refined adjustment methods of daytime chemotherapy payment, as well as the setting and adjustment methods of institution level coefficient under the DIP payment, to improve the scientific score formation mechanism and dynamic adjustment mechanism. Method: All hospitalized patients from tertiary hospitals in Xiamen City, Fujian Province from 2021 to 2023 were selected as samples. Univariate and multivariate analyses were conducted on the influencing factors of the medical insurance fund payment amount for hospitalization medical expenses of antitumor drug treatment. The effects of hospitalization days and antitumor drugs on the medical insurance fund payment amount for hospitalization medical expenses, the CV of hospitalization medical expenses and the differences in fees among medical institutions. Results: Antitumor drugs and hospitalization days have a significant impact on the medical insurance fund payment amount for hospitalization medical expenses. Conclusion: Under the DIP payment, it is recommended to set an auxiliary catalog of tumor drugs for some tumor diseases, calculate the scores for daytime chemotherapy and differentiate them effectively from non-daytime chemotherapy for more scientific and accurate payment, adjust the institutional level coefficient for different medical institutions and improve the refined management of medical insurance.

Key words

DIP / antitumor drugs / drug auxiliary catalog / daytime chemotherapy / refined management

Cite this article

Download Citations
Research on the Drug Auxiliary Catalog for Tumor Diseases and the Payment Policy of Daytime Chemotherapy Under the DIP Payment[J]. China Health Insurance. 2024, 0(9): 64-69 https://doi.org/10.19546/j.issn.1674-3830.2024.9.009

References

[1] HAN B, ZHENG R, ZENG H, et al.Cancer incidence and mortality in China, 2022[J]. Journal of the national cancer center, 2024, 4(1): 47-53.
[2] 宋丹红,赵方辉,张勇.我国癌症经济负担的成因与思考[J].中国公共卫生,2023,39(02):137-140.
[3] 谢杏梅,高悦.国家医保谈判新型抗肿瘤药物的发展变化[J].中南药学,2023,21(05):1393-1398.
[4] 曾雪琴,于伟.化疗患者DIP辅助目录构建研究[J].中国卫生经济,2023,42(01):37-41+56.
[5] 曾欣,马颖颖.以健康为导向的DIP创新机制与实现路径[J].卫生经济研究,2023,40(02):52-56.
[6] 蒋婷,袁明勇,郑玲利,等.基于SWOT分析模型评价我院抗肿瘤药物临床应用监管效果[J].肿瘤药学,2023,13(05):631-636.
[7] 马雷,柳俊杰,龚海英,等.DRG付费下恶性肿瘤住院费用管理策略及评价视角[J].中国医疗保险,2022(12):73-77.
[8] 国家医疗保障局. 2023年全国医疗保障事业发展统计公报[EB/OL].(2024-07-25)[2024-08-05].https://www.nhsa.gov.cn/art/2024/7/25/art_7_13340.html.
[9] 卢钰,朱与菁,钟欣益.DRG医保支付方式下的医院伦理困境及对策研究[J].医学与哲学,2024,45(12):25-28.
[10] 付晓光,万泉,柴培培,等.我国职工医保门诊保障的现状及改革思考[J].中国医疗保险,2021(06):36-38.
[11] 顾雪非,聂子潞.价值医疗的概念及实现路径[J].中国普外基础与临床杂志,2021,28(12):1541-1542.
[12] 宣建伟,李幼平.真实世界研究与创新药物价值[J].中国循证医学杂志,2018,18(04):273-276.
[13] 厦门市医疗保障中心.关于开展门诊按病种分值付费(DIP)支付试点工作有关事项的通知[EB/OL].(2024-05-28)[2024-07-02].http://ylbz.xm.gov.cn/zwgk/zfxxgk/ml/ybzx/202405/t20240528_2849133.htm?PROTID=3513.
[14] 厦门市医疗保障中心.关于进一步完善DIP系数动态调整机制的通知[EB/OL].(2024-05-28)[2024-07-02].https://ylbz.xm.gov.cn/zwgk/zfxxgk/ml/ybzx/202405/t20240528_2849144.htm.

Accesses

Citation

Detail

Sections
Recommended

/